A
A Minnich
Researcher at Aventis Pharma
Publications - 6
Citations - 1433
A Minnich is an academic researcher from Aventis Pharma. The author has contributed to research in topics: Internal medicine & Fibrosis. The author has an hindex of 2, co-authored 2 publications receiving 1363 citations.
Papers
More filters
Journal ArticleDOI
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.
Giulia Chinetti,Sophie Lestavel,Bocher,Alan T. Remaley,Bernadette Neve,Inés Pineda Torra,Elisabeth Teissier,A Minnich,Michael C. Jaye,Nicolas Duverger,H B Brewer,Jean-Charles Fruchart,Clavey,Bart Staels +13 more
TL;DR: A regulatory role is identified for PPAR-α andPPAR-γ in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages.
Journal Article
PPAR alpha and PPAR gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABC-1 pathway.
Giulia Chinetti,Sophie Lestavel,Alan T. Remaley,Bernadette Neve,Inés Pineda Torra,A Minnich,Michael Jaye,Nicolas Duverger,H B Brewer,J.C. Fruchart,Clavey,Bart Staels +11 more
TL;DR: A regulatory role is identified for PPAR-alpha andPPAR-gamma in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages.
Journal ArticleDOI
LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis
Benjamin E. Decato,Diana Julie Leeming,Jannie M.B. Sand,Aryeh Fischer,Shuyan Du,Scott M. Palmer,Morten A. Karsdal,Yi Luo,A Minnich +8 more
TL;DR: In this paper , a phase 2 trial showed that twice-daily treatment with BMS-986020, a lysophosphatidic acid receptor 1 (LPA1) antagonist, significantly decreased the slope of forced vital capacity (FVC) decline over 26 weeks compared with placebo.
Journal ArticleDOI
Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
Elizabeth Brown,A Minnich,Arun J. Sanyal,Rohit Loomba,Shuyan Du,J. Schwarz,Richard L. Ehman,Morten A. Karsdal,Diana Julie Leeming,Giovanni Cizza,Edgar D. Charles +10 more
TL;DR: FALCON 1 was a phase IIb study of pegbelfermin in patients with non-alcoholic steatohepatitis (NASH) and stage 3 fibrosis as mentioned in this paper .
Journal ArticleDOI
Analytical and clinical validation of AIM-NASH: a digital pathology tool for artificial intelligence-based measurement of non-alcoholic steatohepatitis histology
Stephen C. Harrison,H. Pulaski,M Vitali,Laryssa Manigat,Hypatia Hou,Susan Madasu,Sara Hoffman,Adam Stanford-Moore,R. Egger,Janani Iyer,Murray B. Resnick,Neel Patel,Cristin Taylor,Shraddha Mehta,R. Myers,Chuhan Chung,Scott D. Patterson,Anne-Sophie Sejling,A Minnich,Vipul A. Baxi,G. Mani Subramanian,Arun J. Sanyal,Quentin M. Anstee,Rohit Loomba,Vlad Ratziu,Katy Wack +25 more